Useful tips

Why did Exelixis stock drop?

Why did Exelixis stock drop?

The stock price of Exelixis (NASDAQ: EXEL), a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21\% drop over the last five trading days, after the company announced a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients.

Is EXEL stock a good buy?

Valuation metrics show that Exelixis, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of EXEL, demonstrate its potential to outperform the market.

Will EXEL stock go up?

Will Exelixis stock price grow / rise / go up? Yes. The EXEL stock price can go up from 16.400 USD to 16.690 USD in one year.

READ:   What happened between Levon Helms and Robbie Robertson?

What type of company is Exelixis?

biotechnology company
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options.

Should I sell Exelixis stock?

Is Exelixis a buy right now? 11 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Exelixis in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Exelixis stock.

Is Exelixis a pharmaceutical company?

Exelixis Pharmaceuticals, Inc. Alameda, California, U.S.

Is Exelixis a good company to work for?

It is a good company, but lacks a long-term strategic plan, no control of spending money. CEO make mistakes for crucial decisions, and the BOD does not do the job as it supposed to do.

When did Exelixis go public?

April 10, 2000
Our mailing address is 1851 Harbor Bay Parkway, Alameda, CA 94502. Our phone number is (650) 837-7000. When did Exelixis go public? Exelixis stock was first publicly traded on NASDAQ on April 10, 2000.

READ:   Where is the statue of Mussolini?

How many employees does Exelixis have?


Formerly Exelixis Pharmaceuticals, Inc. (1994-2000)
Total assets US$ 655.29 million (2017)
Total equity US$ 284.96 million (2017)
Number of employees ca. 484 (12/2019)

How many people work for Exelixis?

507 employees
Exelixis is a medium health care company with 507 employees and an annual revenue of $853.8M that is headquartered in Alameda, CA.

What does Exelixis Inc do?

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

What does Exelixis mean?

Exelixis comes from the Greek word for “evolution.” Visit to see how we’re working to evolve #cancer treatment.

What are the price targets for Exelixis’ stock?

7 brokerages have issued 12 month price targets for Exelixis’ stock. Their forecasts range from $19.00 to $48.00. On average, they expect Exelixis’ stock price to reach $28.29 in the next twelve months. This suggests a possible upside of 63.9\% from the stock’s current price. View Analyst Price Targets for Exelixis.

READ:   Why are scientists arrogant?

When is Exelixis’ next quarterly earnings announcement?

Exelixis is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021. View our earnings forecast for Exelixis. How were Exelixis’ earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Thursday, August, 5th.

Who is the CEO of Exelixis?

32 employees have rated Exelixis CEO Michael M. Morrissey on Michael M. Morrissey has an approval rating of 79\% among Exelixis’ employees. Who are some of Exelixis’ key competitors?

What companies do other Exelixis investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).